BCS Core

BCS核心

• 批准号: 10491124
• 负责人: Julie Lynn Boerner
• 金额: $ 14.79万
• 依托单位: WAYNE STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-20 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10491124
• 关键词: African American; Ancillary Study; Biological; Biological Assay; Biological Specimen database; Cancer Patient; Charge; Clinical; Collection; Communities; Comprehensive Cancer Center; Confidentiality of Patient Information; Core Facility; Data; Development; Diagnosis; Disease; Doctor of Philosophy; Ensure; Ethnic Origin; Freezing; Future; Genomics; Goals; Guidelines; Health Disparities Research; Histologic; Human; Institutes; Institutional Review Boards; Malignant Neoplasms; Malignant neoplasm of lung; Microscopic; Molecular; Nature; Outcome; Pathologic; Pathologist; Pathology; Patient Care; Patients; Process; Prognosis; Prognostic Marker; Program Research Project Grants; Protocols documentation; Quality Control; Race; Reduce health disparities; Research; Research Personnel; Research Project Grants; Research Support; Resource Development; Resource Sharing; Sampling; Sampling Studies; Science; Services; Specimen; Stains; System; Technology; Testing; Therapeutic Intervention; Time; Tissue Microarray; Tissue Sample; Tissue Stains; Tissues; Translational Research; Update; Xenograft procedure; accurate diagnosis; base; biobank; cancer biomarkers; cancer health disparity; cancer risk; cancer therapy; design; health disparity; human tissue; improved; innovation; metropolitan; minority patient; molecular array; neoplasm resource; new therapeutic target; novel; patient population; programs; therapeutic biomarker; therapeutic development

Project Summary The Biospecimen Core directed by the Director of the Biobanking and Correlative Sciences (BCS) Core at Karmanos Cancer Institute, Dr. Julie Boerner, PhD and co-directed by Dr. Fulvio Lonardo, expert lung cancer pathologist will provide the highest quality biological specimens to support the research of investigators for this P20 application. This Core facility is charged with collecting, banking, and transferring fresh and frozen human tissue samples for investigative purposes. As part of this process, the Biospecimen Core will provide correlative clinical information for biospecimens while maintaining strict patient confidentiality, using the well-established Honest Broker system, and ensuring that requesting investigators have proper protocol review and IRB approval. This specific collection of biospecimens is focused on overcoming the lack of biospecimens from minority patients that plagues race/ethnicity-related researcher questions. The goal of this P20 SPORE Core is to ensure that high-quality biospecimens, collected while ensuring compliance with federal and institutional guidelines, are delivered in a timely manner to P20 SPORE investigators and to provide pathologic and molecular analytic expertise to support the innovative and translational cancer health disparities research projects in this application. The specific aims of Biospecimen Core are the following: Specific Aim 1: To collect, process and bank cancer tissue and associated biological samples with ongoing quality control to ensure timely distribution of appropriately diagnosed, high-quality samples to investigators and collaborators on all P20 SPORE projects for molecular and genomic analysis, for culture and for xenograft assays, and for ancestry informative markers to further define patient race; Specific Aim 2: Perform high quality immunohistochemical staining and provide pathological interpretation of stained tissue sections to investigators and collaborators on all P20 SPORE projects; Specific Aim 3: Generate tissue microarrays using samples from African American cancer patients for use in future projects and made available to the broader research community to support expanded efforts in the reduction of cancer health disparities; Specific Aim 4: To maintain and update a central Detroit P20 SPORE database of biospecimens from cancer patients collected at KCI that is annotated with demographic, clinical, and pathologic data, and provide access to data and specimens; and Specific Aim 5: To actively participate in the design of pathology/ancillary studies of P20 SPORE projects, the Developmental Research Program projects, and projects for consideration for a full P50 SPORE application, including providing input on suitability for samples for studies proposed, histologic characterization, immunohistochemical analyses, and microscopic scoring, and construction of study specific tissue microarrays. Together, these aims will allow the Biospecimen Core to have a significant clinical impact in this P20 application, as it has a large collection of valuable and appropriate specimens that are immediately available to the research projects.

项目摘要 由生物库和相关科学(BCS)核心主任指导的Biosecimen核心 卡马诺斯癌症研究所，Julie Boerner博士，博士，由Fulvio Lonardo博士共同指导，肺癌专家 病理学家将提供最高质量的生物标本来支持研究人员对此的研究 P20应用。这个核心设施负责收集、储存和转移新鲜和冷冻的人 用于调查目的的组织样本。作为这一进程的一部分，Biosecimen核心将提供相关的 生物检疫的临床信息，同时严格保密患者，使用公认的 诚实的经纪人制度，并确保提出请求的调查人员有适当的方案审查和IRB批准。 这一特定的生物旋毛虫集合的重点是克服来自少数族裔的生物旋毛虫的缺乏。 困扰种族/民族相关研究人员问题的患者。这个P20孢子核心的目标是确保 在确保遵守联邦和机构指南的情况下收集的高质量生物检疫剂是 及时交付给P20孢子调查人员，并提供病理和分子分析 支持创新和转化型癌症健康差异研究项目的专业知识 申请。Biosecimen Core的具体目标如下：具体目标1：收集、加工和 对癌症组织和相关生物样本进行持续质量控制，以确保及时分发 向所有P20孢子项目的研究人员和合作者提供经过适当诊断的高质量样本 用于分子和基因组分析、培养和异种移植分析，以及祖先信息标记 进一步确定患者种族；具体目标2：进行高质量的免疫组织化学染色并提供 对所有P20孢子的研究人员和合作者的染色组织切片的病理解释 项目；具体目标3：使用非裔美国癌症患者的样本生成组织微阵列 在未来的项目中使用，并提供给更广泛的研究界，以支持在 减少癌症健康差距；具体目标4：维持和更新底特律中心的P20孢子 在KCI收集的来自癌症患者的生物样本数据库，带有人口统计学，临床， 和病理数据，并提供获取数据和标本的途径；具体目标5：积极参与 发育性研究项目P20孢子项目的病理学/辅助研究设计 项目，以及考虑完整的P50孢子应用的项目，包括提供关于适宜性的输入 用于建议研究的样本、组织学特征、免疫组织化学分析和显微镜检查 评分和构建研究特定的组织微阵列。这些目标加在一起，将使生物质学家 核心在这个P20应用中有重大的临床影响，因为它有大量有价值的和 可立即用于研究项目的适当标本。